GlassScriptPhysician profile
Louisa M Tift
NPI 1972645307
$4,541.21
in general payments reported to CMS, 2019-2025
23 companies · $1,063 in 2025
The $1,063 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $395 · 2020: $104 · 2021: $96.97 · 2022: $919 · 2023: $948 · 2024: $1,016 · 2025: $1,063.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,787 · Education: $239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,787.21 |
| Education | $238.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $753.97 | 2019-2025 | Tremfya, Simponi, Stelara |
| Abbvie INC. | $744.78 | 2020-2025 | Rinvoq |
| Lilly USA, LLC | $578.88 | 2022-2025 | Taltz, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $389.43 | 2019-2025 | Dupixent |
| Pfizer INC. | $331.10 | 2020-2025 | |
| Genzyme Corporation | $318.31 | 2021-2025 | |
| Incyte Corporation | $212.04 | 2022-2025 | Opzelura |
| Leo Pharma INC. | $205.93 | 2019-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $194.17 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $165.46 | 2023-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $156.99 | 2022-2025 | Ilumya |
| Dermavant Sciences, INC. | $108.54 | 2022-2024 | Vtama |
| Amgen INC. | $89.19 | 2024-2025 | Otezla, Otezla |
| Helsinn Therapeutics (U.S.), INC. | $62.63 | 2022-2023 | Valchlor |
| Sanofi-Aventis U.S. LLC | $48.27 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $32.77 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Galderma Laboratories, L.P. | $30.69 | 2024-2025 | Aklief |
| Cipher Pharmaceuticals US LLC | $28.42 | 2025 | Natroba, Spinosad |
| Dermira, INC. | $21.63 | 2019 | |
| Organon LLC | $19.96 | 2025 | |
| Aclaris Therapeutics, INC. | $19.90 | 2019 | |
| Integra Lifesciences Corporation | $15.72 | 2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Merck Sharp & Dohme LLC | $12.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louisa Tift listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.